FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130123102> ?p ?o ?g. }

• W3130123102 endingPage "17" @default.
• W3130123102 startingPage "PS14" @default.
• W3130123102 abstract "Abstract Gene expression profiles of some subtypes of breast cancer were shown to correspond to the profiles of the basal or luminal mammary stem/progenitor cell-enriched epithelial cells implicating the mammary stem cells (MaSCs) as tumor-initiating cells for certain types of breast cancer. Moreover, there is growing evidence that MaSCs may initiate neoplastic transformation when dysregulated in mouse models. We have previously reported an increased frequency of the MaSC-enriched Lin-/CD49fhigh/CD24+ basal cells in old mice (&gt;27 month) compared to young ones (2-4 month) along with an increase of hyperplasic lesions. Gene expression profile revealed an increase of immune and inflammatory responses in old basal cells and stroma cells indicating that aging-induced immune and inflammatory responses might initiate basal cell expansion and transformation. Our preliminary data on mice using rapamycin, an immune and inflammation inhibitor, were very encouraging so we decided to start a clinical window trial (NCT02642094) to test whether rapamycin could reduce biomarkers associated with progression to invasive breast cancer and MaSC numbers in postmenopausal patients with atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS). The patients enrolled in the trial took rapamycin (sirolimus, 2mg/day) for 5-7 days with 3-7 days of washout before surgery. The adjacent non-tumor surgical tissues were used for the measurements of sphere formation efficiency (SFE) of the basal and luminal cells. The control group were patients with ADH/DCIS who did not take the drug. Rapamycin treatment significantly diminished the SFE of the basal MaSC. Immunohistochemical staining of the biopsies and surgical tissues showed that rapamycin treatment significantly decreased the levels of COX2 (an inflammation marker) and p16 (a senescence marker), and moderately increased p62 (an autophagy marker). Furthermore, rapamycin significantly reduced the proliferation marker Ki67 staining. In conclusion, rapamycin inhibits MaSCs function and senescence and inflammation features in human mammary glands. Whether the suppression of the senescence-associated inflammatory responses is the mechanism by which rapamycin suppresses MaSC function is under investigation. Citation Format: Hakim Bouamar, Larry Broome, Xiang Gu, Alia Nazarullah, Andrew Brenner, Virginia Kaklamani, Ismail Jatoi, Lu-Zhe Sun. Rapamycin inhibits stem cell function and diminishes inflammation and senescence markers in human mammary gland [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS14-17." @default.
• W3130123102 created "2021-03-01" @default.
• W3130123102 creator A5009639926 @default.
• W3130123102 creator A5037952411 @default.
• W3130123102 creator A5040443777 @default.
• W3130123102 creator A5047918797 @default.
• W3130123102 creator A5058839084 @default.
• W3130123102 creator A5064316689 @default.
• W3130123102 creator A5083922162 @default.
• W3130123102 creator A5088464876 @default.
• W3130123102 date "2021-02-15" @default.
• W3130123102 modified "2023-09-27" @default.
• W3130123102 title "Abstract PS14-17: Rapamycin inhibits stem cell function and diminishes inflammation and senescence markers in human mammary gland" @default.
• W3130123102 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps14-17" @default.
• W3130123102 hasPublicationYear "2021" @default.
• W3130123102 type Work @default.
• W3130123102 sameAs 3130123102 @default.
• W3130123102 citedByCount "0" @default.
• W3130123102 crossrefType "journal-article" @default.
• W3130123102 hasAuthorship W3130123102A5009639926 @default.
• W3130123102 hasAuthorship W3130123102A5037952411 @default.
• W3130123102 hasAuthorship W3130123102A5040443777 @default.
• W3130123102 hasAuthorship W3130123102A5047918797 @default.
• W3130123102 hasAuthorship W3130123102A5058839084 @default.
• W3130123102 hasAuthorship W3130123102A5064316689 @default.
• W3130123102 hasAuthorship W3130123102A5083922162 @default.
• W3130123102 hasAuthorship W3130123102A5088464876 @default.
• W3130123102 hasConcept C121608353 @default.
• W3130123102 hasConcept C126322002 @default.
• W3130123102 hasConcept C134018914 @default.
• W3130123102 hasConcept C142724271 @default.
• W3130123102 hasConcept C201750760 @default.
• W3130123102 hasConcept C203014093 @default.
• W3130123102 hasConcept C2776914184 @default.
• W3130123102 hasConcept C2778024521 @default.
• W3130123102 hasConcept C2779256057 @default.
• W3130123102 hasConcept C2779306644 @default.
• W3130123102 hasConcept C2779492189 @default.
• W3130123102 hasConcept C2780862961 @default.
• W3130123102 hasConcept C28328180 @default.
• W3130123102 hasConcept C2993273003 @default.
• W3130123102 hasConcept C502942594 @default.
• W3130123102 hasConcept C522857546 @default.
• W3130123102 hasConcept C530470458 @default.
• W3130123102 hasConcept C555283112 @default.
• W3130123102 hasConcept C71924100 @default.
• W3130123102 hasConcept C86803240 @default.
• W3130123102 hasConcept C8891405 @default.
• W3130123102 hasConcept C95444343 @default.
• W3130123102 hasConceptScore W3130123102C121608353 @default.
• W3130123102 hasConceptScore W3130123102C126322002 @default.
• W3130123102 hasConceptScore W3130123102C134018914 @default.
• W3130123102 hasConceptScore W3130123102C142724271 @default.
• W3130123102 hasConceptScore W3130123102C201750760 @default.
• W3130123102 hasConceptScore W3130123102C203014093 @default.
• W3130123102 hasConceptScore W3130123102C2776914184 @default.
• W3130123102 hasConceptScore W3130123102C2778024521 @default.
• W3130123102 hasConceptScore W3130123102C2779256057 @default.
• W3130123102 hasConceptScore W3130123102C2779306644 @default.
• W3130123102 hasConceptScore W3130123102C2779492189 @default.
• W3130123102 hasConceptScore W3130123102C2780862961 @default.
• W3130123102 hasConceptScore W3130123102C28328180 @default.
• W3130123102 hasConceptScore W3130123102C2993273003 @default.
• W3130123102 hasConceptScore W3130123102C502942594 @default.
• W3130123102 hasConceptScore W3130123102C522857546 @default.
• W3130123102 hasConceptScore W3130123102C530470458 @default.
• W3130123102 hasConceptScore W3130123102C555283112 @default.
• W3130123102 hasConceptScore W3130123102C71924100 @default.
• W3130123102 hasConceptScore W3130123102C86803240 @default.
• W3130123102 hasConceptScore W3130123102C8891405 @default.
• W3130123102 hasConceptScore W3130123102C95444343 @default.
• W3130123102 hasIssue "4_Supplement" @default.
• W3130123102 hasLocation W31301231021 @default.
• W3130123102 hasOpenAccess W3130123102 @default.
• W3130123102 hasPrimaryLocation W31301231021 @default.
• W3130123102 hasRelatedWork W1995437350 @default.
• W3130123102 hasRelatedWork W2043890160 @default.
• W3130123102 hasRelatedWork W2083402036 @default.
• W3130123102 hasRelatedWork W2104682960 @default.
• W3130123102 hasRelatedWork W2369025615 @default.
• W3130123102 hasRelatedWork W2612699275 @default.
• W3130123102 hasRelatedWork W3029416930 @default.
• W3130123102 hasRelatedWork W3044706605 @default.
• W3130123102 hasRelatedWork W3094837335 @default.
• W3130123102 hasRelatedWork W3172687238 @default.
• W3130123102 hasVolume "81" @default.
• W3130123102 isParatext "false" @default.
• W3130123102 isRetracted "false" @default.
• W3130123102 magId "3130123102" @default.
• W3130123102 workType "article" @default.